trending Market Intelligence /marketintelligence/en/news-insights/trending/SgfPZkVyAqKVkP6RTw4AXw2 content esgSubNav
In This List

US FDA rejects AcelRx Pharmaceuticals' pain drug

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation

Blog

Using Credit Analytics to Avoid Mispricing Insurance Premiums

Blog

Post-Webinar Q&A: Integrating Climate Risks into Credit Risk Portfolios


US FDA rejects AcelRx Pharmaceuticals' pain drug

AcelRx Pharmaceuticals Inc. said the U.S. Food and Drug Administration rejected its new drug application for DSUVIA to treat moderate-to-severe acute pain.

AcelRx submitted the application in December 2016. In a complete response letter, the U.S. FDA requested additional data on at least 50 patients and certain labeling changes in usage directions.

The 2016 application was supported by results from the entire ARX-04 clinical program, including data from four trials that showed improvement in pain intensity within 15 to 30 minutes of dosage.

"We believe the recommendations stated in the CRL are manageable and plan to fully cooperate with the FDA," AcelRX CEO Vincent Angotti said in a statement.